宫颈癌筛查方案对早产的影响:决策与成本效果分析
作者认为30岁以下女性每3年筛查及后续治疗获得的生命年有限,可能带来显著围产期不良影响,计划生育的女性或可从更审慎的筛查策略中获益。
要点
- 自21岁起每3年筛查较自30岁起每5年筛查增加9%母亲生命年,降低67%宫颈癌病例和75%宫颈癌死亡。
- 作者认为计划生育的女性或可从更审慎的筛查策略中获益,需权衡癌症与早产风险。
核心结论
- 30岁以下女性每3年宫颈癌筛查及后续治疗获得的母亲生命年有限,但可能带来显著的围产期不良影响。
- 作者认为计划生育的女性或可从更审慎的筛查策略中获益,需同时考虑其癌症和早产风险。
研究设计与样本
- 决策与成本效果分析,在10万名女性虚拟队列中比较8种基于细胞学的筛查方案,方案在筛查起始年龄(21、24、25、27或30岁)和筛查间隔(3年或5年)上不同。
- 使用微模拟筛查分析模型估算宫颈上皮内瘤变诊断数、转化区大环切除术(LLETZ)、获得生命年、宫颈癌病例、死亡及筛查和治疗成本,并以LLETZ数量计算额外早产、后续新生儿疾病、死亡及相关成本。
主要发现
- 每10万名女性中LLETZ数量从最密集筛查(自21岁起每3年)的9612例到最不密集筛查(自30岁起每5年)的4646例不等。
- 与最不密集方案相比,最密集方案使母亲获得生命年增加9%(10728 vs 9839),宫颈癌病例减少67%(52 vs 158),宫颈癌死亡减少75%(4 vs 16)。
- 每增加一例早产所对应的母亲获得生命年数为68至258,每获得一个母亲生命年对应的总费用分别为7212美元和2329美元。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the effect of age at initiation and interval of cervical cancer screening in women of reproductive age on the risk of future preterm birth and subsequent adverse neonatal outcome relative to maternal life-years gained and cost of both screening and preterm birth. METHODS: In this decision and cost-effectiveness analysis, we compared eight cytology-based screening programs varying in age of onset (21, 24, 25, 27, or 30 years) and screening interval (3 or 5 years) in a fictive cohort of 100,000 women. We used the microsimulation screening analysis model to estimate number of cervical intraepithelial neoplasia diagnoses, large loop excisions of the transformation zone (LLETZs), life-years gained, cervical cancer cases, deaths, and costs of screening and treatment. We used the number of LLETZs to calculate additional preterm births, subsequent neonatal morbidity, mortality, and associated costs. RESULTS: The number of LLETZs per 100,000 women varied from 9,612 for the most intensive screening (every 3 years from age 21 years) to 4,646 for the least intensive screening (every 5 years from age 30 years). Compared with the least intensive program, the most intensive program increased maternal life-years gained by 9% (10,728 compared with 9,839), decreased cervical cancer cases by 67% (52 compared with 158), and cervical cancer deaths by 75% (four compared with 16) at the expense of 250% (158 compared with 45) more preterm births and 320% (four compared with one) more neonatal deaths while increasing total costs by $55 million ($77 compared with $23 million). The number of maternal life-years gained per additional preterm birth varied from 68 to 258 with subsequent total costs per maternal life-years gained of $7,212 and $2,329. CONCLUSION: Cervical cancer screening every 3 years and subsequent treatment in women aged younger than 30 years yield limited life-years but may have substantial perinatal adverse effects. Consequently, women who plan to have children may benefit from a more cautious screening approach, taking into account their risk for both cancer and preterm birth.
引用
- Kamphuis EI, Naber SK, Danhof NA, et al. Effect of Cervical Cancer Screening Programs on Preterm Birth: A Decision and Cost-Effectiveness Analysis. Obstet Gynecol. 2017. PMID: 29112652. doi:10.1097/AOG.0000000000002366
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。